Skip to main content

Table 2 Risks of venous/arterial diseases in PCOS women when compared with non-PCOS controls

From: Risks, benefits size and clinical implications of combined oral contraceptive use in women with polycystic ovary syndrome

Variable

Risk (95%CI)a

Reference

VTE

1.55 (1.10–2.19)

ST Bird et al., 2013

3.26 (2.60–4.08)

EM Okoroh et al., 2012

CHD

1.50 (0.70–2.90)

S Wild et al., 2000

1.25 (1.07–1.47)

CG Solomon et al., 2002

1.63 (0.96–2.78)

SA Anderson et al., 2014

1.27 (1.10–1.46)

EM Okoroh et al., 2012

1.44 (1.13–1.84)

L Zhao et al., 2016

Stroke

2.80 (1.10–7.10)

S Wild et al., 2000

1.30 (0.97–1.74)

CG Solomon et al., 2002

1.61 (0.94–3.315)

SA Anderson et al., 2014

2.20 (1.50–3.20)

T Matthesen et al., 2015

CHD/Stroke

2.02 (1.47–2.76)

PCM de Groot et al., 2011

4.24 (1.96–9.17)

D Cibula et al., 2000

  1. VTE Venous thromboembolism, CHD Coronary heart disease, CI 95% confidence interval
  2. aRelative risk or hazard risk or odds ratio